Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Antitumor cell activity in glioblastoma is controlled by blocking the triggering receptor expressed on myeloid cells 2.

2.

Momelotinib, a JAK inhibitor, has FDA approval to treat adult myelofibrosis in anemic patients.

3.

MCh in Gynecologic Oncology: Admission, Medical School, Fees, Qualifications Information

4.

Immune cell homing hydrogel-based platform captures dendritic cells to process mRNA from cancer vaccines

5.

COVID-19 mRNA vaccines could unlock the next revolution in cancer treatment


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot